Previous Close | 4.5900 |
Open | 4.4400 |
Bid | 0.0000 x 900 |
Ask | 0.0000 x 1000 |
Day's Range | 4.4400 - 4.8400 |
52 Week Range | 2.6200 - 26.7000 |
Volume | |
Avg. Volume | 301,727 |
Market Cap | 186.802M |
Beta (5Y Monthly) | 1.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.2090 |
Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for ORIC
Horizon (HZNP) enters into a collaboration and option agreement with Q32 Bio to develop the latter's ADX-914 for treating autoimmune diseases.
Three ongoing single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, all expected to report initial data in 1H 2023 Cash and investments of $237.8 million expected to fund current operating plan into 2H 2024 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeu
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...